Haemonetics Corporation (HAE) - Fiscal 2026 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 28, 2026
Business Overview: Haemonetics is a global medical technology company operating in three segments: Plasma (collection devices and software), Blood Center (blood collection and processing), and Hospital (Interventional Technologies and Blood Management Technologies). The company focuses on improving healthcare quality and efficiency through innovative solutions for plasma collection, blood management, and hospital procedures.
Key Financial Metrics
| Metric (in thousands, except per share) | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Net Revenues | $1,334,027 | $1,360,824 | (2.0)% |
| Gross Profit | $787,586 | $748,958 | 5.2% |
| Gross Margin | 59.0% | 55.0% | +400 bps |
| Operating Income | $156,734 | $221,817 | (29.3)% |
| Operating Margin | 11.7% | 16.3% | -460 bps |
| Net Income | $97,308 | $167,679 | (42.0)% |
| Diluted EPS | $2.05 | $3.31 | (38.1)% |
| Cash and Equivalents | $245,440 | $306,763 | (20.0)% |
| Total Debt (Gross) | $1,224,580 | $1,224,788 | ~0% |
| Net Debt Position | ($979,140) | ($918,025) | Worsened |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 2.0% primarily due to portfolio transitions in the Plasma segment (CSL Plasma customer transition) and the divestiture of the Whole Blood product line in the prior year, which represented approximately $153 million of nonrecurring revenue in FY2025. These declines were partially offset by growth in the Hospital segment.
- Operating Income Drop: Operating income fell 29.3% driven significantly by an $86.5 million impairment charge related to intangible assets (primarily the Attune Medical asset group and HemoAssay intellectual property). This was partially offset by pricing benefits and reduced restructuring costs.
- Segment Performance:
- Plasma: Revenue down 2.0% (reported) due to lower volumes in North America.
- Blood Center: Revenue down 15.3% due to the Whole Blood divestiture.
- Hospital: Revenue up 4.3% driven by Hemostasis Management and Transfusion Management growth, offset by lower Interventional Technologies sales.
- Debt Management: The company repaid the remaining $300 million of its 2026 Convertible Notes at maturity in March 2026, funded by cash on hand and a drawdown on its revolving credit facility.
Guidance, Outlook, and Risks
- Strategic Acquisitions: Completed the acquisition of Vivasure Medical Limited for $164.4 million in January 2026 to expand the Hospital segment's vascular closure portfolio with the PerQseal Elite system.
- Restructuring: Continuing the "Market and Regional Alignment Initiative" to improve operational performance and reduce costs. Cumulative charges under this initiative were $5.6 million as of March 28, 2026.
- Share Repurchases: Under a $500 million program approved in April 2025, the company repurchased $175 million of stock in FY2026. Approximately $325 million remains authorized.
- Key Risks:
- Customer Concentration: Ten largest customers accounted for 44% of FY2026 revenue; one Plasma customer accounted for 13%.
- Regulatory: Ongoing compliance with EU MDR/IVDR and FDA requirements (e.g., PMA for PerQseal Elite).
- Goodwill Impairment Risk: The Interventional Technologies reporting unit has a narrow margin of safety (fair value exceeded carrying value by only 6%), making it sensitive to changes in revenue growth or discount rates.
- Supply Chain: Exposure to raw material costs, tariffs, and geopolitical instability.
Investor Verification Checklist
- Impairment Sustainability: Verify the assumptions behind the $86.5 million intangible impairment charge and assess the risk of future impairments, particularly for the Interventional Technologies unit.
- Plasma Customer Transition: Confirm the timeline and revenue impact of the CSL Plasma customer transition and the adoption of new technologies (Persona PLUS, Express Plus).
- Vivasure Integration: Monitor the commercialization progress and regulatory status (FDA PMA) of the PerQseal Elite system acquired from Vivasure.
- Debt Covenants: Review compliance with the 2024 Revised Credit Facilities covenants, specifically the consolidated net leverage ratio, given the recent drawdown on the revolving facility.
- Goodwill Headroom: Analyze the sensitivity of the Interventional Technologies reporting unit's fair value to changes in discount rates and revenue growth projections.